Hodgkin’s Lymphoma

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (02-26-2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed,... Continue Reading

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma (01-16-2014)

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant, according to the results of a study presented... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (09-16-2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (05-15-2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (02-11-2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma (01-2-2013)

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according to the results of a study presented at the 19th... Continue Reading

Children with Favorable-Risk Hodgkin’s Lymphoma May Benefit from Limited Radiation Therapy (07-6-2012)

Children with favorable-risk Hodgkin’s lymphoma who achieve a complete early response to chemotherapy may not require radiation therapy or may undergo limited radiation therapy, according to the results of a study published in the Journal of the American... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (05-17-2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (03-26-2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (03-14-2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

« Previous PageNext Page »